Key facts
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G for BioXcel Therapeutics, Inc. Common Stock, par value $0.001 (BTAI).
- Disclosed ownership: 7%.
- Date of event: 31 Mar 2026.
ARMISTICE CAPITAL, LLC - 31 Mar 2026 SCHEDULE 13G Report for BioXcel Therapeutics, Inc. Common Stock, par value $0.001 (BTAI)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- BTAI
- Shares outstanding
- 27,093,277 shares
- Disclosed Ownership
- 1,910,076 shares
- Ownership
- 7%
- Form type
- SCHEDULE 13G
- Filing time
- 15 May 2026, 11:09:47 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Key filing fact
ARMISTICE CAPITAL, LLC disclosed 7% ownership in BioXcel Therapeutics, Inc. Common Stock, par value $0.001 (BTAI) on 31 Mar 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2026, 11:09.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 7% | 1,910,076 | 0 | 1,910,076 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 7% | 1,910,076 | 0 | 1,910,076 | /s/ Steven Boyd | Steven Boyd |
CIK / CUSIP context first